Clinical features and prognosis in CD10- pre-B acute lymphoblastic leukemia
10.3760/cma.j.issn.0253-2727.2017.01.004
- VernacularTitle: CD10阴性的前B急性淋巴细胞白血病的临床特征以及预后分析
- Author:
Xiaoyuan GONG
1
;
Ying WANG
;
Bingcheng LIU
;
Hui WEI
;
Chunlin ZHOU
;
Dong LIN
;
Kaiqi LIU
;
Shuning WEI
;
Benfa GONG
;
Guangji ZHANG
;
Yuntao LIU
;
Xingli ZHAO
;
Yan LI
;
Runxia GU
;
Shaowei QIU
;
Yingchang MI
;
Jianxiang WANG
Author Information
1. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China
- Publication Type:Journal Article
- Keywords:
Leukemia, lymphoid;
Neprilysin;
Gene rearrangement, MLL;
Prognosis
- From:
Chinese Journal of Hematology
2017;38(1):17-21
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical features and prognosis of acute lymphoblastic leukemia patients with immunophenotype of CD10-pre-B (CD10- pre B-ALL) .
Methods:6 adult cases with CD10- pre B-ALL immunophenotypes were analyzed retrospectively, related literatures were reviewed to clarify these kind of patients’ clinical features and prognosis.
Results:CD10- pre B-ALL occurred in 1.5% of ALL, 1.8% of B-ALL and 11.5% of pre B-ALL respectively. All the 6 patients were male with the median age as 33.5 years old, the median white blood cells was 101.78×109/L, MLL-AF4 fusion transcripts were evident in all cases. Complete remission (CR) was achieved in 5 patients after first induction chemotherapy, 1 patient failed to respond to induction therapy, and got CR after 3 courses of chemotherapy. 2 patients underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) in CR1, 1 patient relapsed in the short term and underwent allo-HSCT in CR2. 1 patient was still waiting for allo-HSCT. Of the 2 patients who didn’t receive transplantation, 1 died following a relapse, the other remained to be in CR.
Conclusions:CD10- pre B-ALL was a rare but distinct subtype in adult ALL characterized by male dominance, high onset white blood cells and MLL rearrangement rate. Conventional chemotherapy produced a high response rate but more likely relapse, allo-HSCT may have the potential to improve the prognosis of these patients.
